We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other large-cap stocks.

The big and large-cap stocks have spearheaded the rally in the past two years, but Wall Street’s expectations have gotten ahead of many of their fundamentals. The Nasdaq briefly entered correction territory as the stock market cooled over the past week due to tariff fears and a perceived slowdown in the growth of AI, which then spilled into the data center industry.

Wall Street is now reassessing the growth premium they are paying for many of these large-cap stocks. A lot of them have tumbled in the past week and have done so in a much more severe way than the broader market.

That said, large companies have staying power, and many of them could now be undervalued.

Methodology

For this article, I screened the worst-performing large-cap stocks ($10 billion to $100 billion) year-to-date.

I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

A research facility with medical professionals surrounded by diagnostic equipment.

Illumina, Inc. (NASDAQ:ILMN)

Number of Hedge Fund Holders In Q4 2024: 61

Illumina, Inc. (NASDAQ:ILMN) is a biotech company.

The stock is down significantly so far in 2025 as Illumina, Inc. (NASDAQ:ILMN) was placed on China’s "Unreliable Entities List." This could make it a potential loser if sanctions and trade restrictions keep getting tougher. China accounts for approximately 7% of Illumina’s revenue.

Moreover, Illumina, Inc. (NASDAQ:ILMN)’s Q4 results slightly exceeded analyst expectations, but this wasn’t enough to offset its weak guidance for this year.

Management projected revenue growth of low single digits and non-GAAP EPS between $4.50-$4.65. Illumina’s fiscal year 2024 revenue decreased by 2% year-over-year to $4.33 billion.

The consensus price target of $149.25 implies 74.17% upside.

Illumina, Inc. (NASDAQ:ILMN) stock is down 35.88% year-to-date.

Overall ILMN ranks 3rd on our list of the large-cap stocks that are plunging so far in 2025. While we acknowledge the potential of ILMN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ILMN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

 

Disclosure: None. This article is originally published at Insider Monkey.